Moleculin Biotech (MBRX) Institutional Ownership → Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad) Free MBRX Stock Alerts $4.31 -0.01 (-0.23%) (As of 06/10/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Moleculin Biotech (NASDAQ:MBRX)CurrentInstitutional OwnershipPercentage15.52%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$41.94MNumber ofInstitutional Sellers(last 12 months)0 Get MBRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Moleculin Biotech stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data MBRX Institutional Buying and Selling by Quarter Ad Weiss RatingsProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself Moleculin Biotech Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/13/2024 Armistice Capital LLC3,207,417$2.75M0.0%N/A9.600% 1/17/2024 Atticus Wealth Management LLC50,001$43K0.0%N/A0.168% 5/15/2023 Sio Capital Management LLC1,010,956$971K0.5%-2.5%3.407% 7/25/2022 Walker Asset Management LLC20,708$32K0.0%N/A0.072% 4/20/2022 Sigma Planning Corp57,500$102K0.0%+33.7%0.201% 2/2/2022 Sigma Planning Corp43,000$80K0.0%N/A0.150% Get the Latest News and Ratings for MBRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. 11/9/2021 BlackRock Inc.270,402$812K0.0%-2.5%0.947% 9/17/2021 Virtu Financial LLC25,302$93K0.0%N/A0.089% 8/16/2021 Occudo Quantitative Strategies LP29,188$107K0.0%+31.7%0.102% 8/16/2021 State Street Corp59,900$220K0.0%N/A0.210% 8/13/2021 Geode Capital Management LLC237,586$871K0.0%+35.9%0.835% 8/13/2021 Vanguard Group Inc.1,047,529$3.84M0.0%+123.6%3.683% 8/12/2021 XTX Topco Ltd32,997$121K0.0%N/A0.116% 8/5/2021 GSA Capital Partners LLP31,120$114K0.0%N/A0.109% 5/21/2021 Citadel Advisors LLC13,843$56K0.0%N/A0.049% 5/19/2021 Squarepoint Ops LLC28,904$118K0.0%+134.2%0.102% 5/18/2021 Cubist Systematic Strategies LLC26,624$109K0.0%N/A0.094% 5/18/2021 Citadel Advisors LLC13,843$56K0.0%N/A0.049% 5/14/2021 Occudo Quantitative Strategies LP22,158$90K0.0%N/A0.078% 5/12/2021 Northern Trust Corp50,731$207K0.0%-43.1%0.178% 5/12/2021 Geode Capital Management LLC174,822$713K0.0%-40.6%0.615% 5/7/2021 BlackRock Inc.239,326$977K0.0%+449.7%0.841% 4/27/2021 Harel Insurance Investments & Financial Services Ltd.10,000$136K0.0%N/A0.035% 4/14/2021 Taylor Cottrill Erickson & Associates Inc.16,964$69K0.0%-83.3%0.060% 2/10/2021 Renaissance Technologies LLC948,503$756K0.0%+6.4%7.901% 11/13/2020 Truist Financial Corp175,000$142K0.0%+25.0%0.284% 8/14/2020 Bank of America Corp DE39,900$39K0.0%N/A0.066% 7/31/2020 UBS Group AG47,538$46K0.0%+40.2%0.079% 5/15/2020 Two Sigma Securities LLC90,062$55K0.0%+556.3%0.169% (Data available from 1/1/2016 forward) MBRX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of MBRX shares? During the previous two years, the following institutional investors and hedge funds held shares of Moleculin Biotech shares: Armistice Capital LLC ($2.75M), Sio Capital Management LLC ($971K), and Atticus Wealth Management LLC ($43K), Walker Asset Management LLC ($32K).Learn more on MBRX's institutional investors. What percentage of Moleculin Biotech stock is owned by institutional investors? 15.52% of Moleculin Biotech stock is owned by institutional investors. Learn more on MBRX's institutional investor holdings. Which institutional investors have been buying Moleculin Biotech stock? The following institutional investors have purchased Moleculin Biotech stock in the last 24 months: Armistice Capital LLC ($3.21M), Atticus Wealth Management LLC ($50.00K), and Walker Asset Management LLC ($20.71K). How much institutional buying is happening at Moleculin Biotech? Institutional investors have bought a total of 3,278,126 shares in the last 24 months. This purchase volume represents approximately $42.39M in transactions. Which Moleculin Biotech major shareholders have been selling company stock? The following institutional investors have sold Moleculin Biotech stock in the last 24 months: Sio Capital Management LLC ($25.90K). How much institutional selling is happening at Moleculin Biotech? Institutional investors have sold a total of 25,897 shares in the last 24 months. This volume of shares sold represents approximately $372.92K in transactions. Related Companies: VCNX Institutional Ownership RVPH Institutional Ownership CLNN Institutional Ownership XLO Institutional Ownership IMRX Institutional Ownership EYEN Institutional Ownership HCWB Institutional Ownership ACXP Institutional Ownership LPCN Institutional Ownership NRXP Institutional Ownership This page (NASDAQ:MBRX) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.